Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary pulmonary hypertension.

A Rashid1, S Lehrman, P Romano

  • 1Department of Pulmonary Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY 10595, USA.

Heart Disease (Hagerstown, Md.)
|December 1, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial Expression of Concern: Disruption of transforming growth factor-β signaling through β-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation.

Oncogene·2026
Same author

Can we optimise the TB response amid funding constraints using evidence-based, cost-effective strategies.

IJTLD open·2026
Same author

National Reporting of Bowel Cancer Care by the National Bowel Cancer Audit (NBOCA) Supports Hospital Teams to Improve care and Outcomes.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Building sustainable TB care systems: managing incentives in private sector engagement.

IJTLD open·2025
Same author

CORRELATION OF FETAL MEASUREMENTS WITH GESTATIONAL AGE IN 144 ABORTED FETUSES: A CROSS-SECTIONAL HOSPITAL-BASED OBSERVATIONAL STUDY.

Georgian medical news·2025
Same author

[Minimally invasive technologies in the treatment of blunt abdominal trauma: a systematic review and meta-analysis. Part 1: primary endpoint - mortality].

Khirurgiia·2025
Same journal

Ximelagatran: a new oral anticoagulant.

Heart disease (Hagerstown, Md.)·2003
Same journal

Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W).

Heart disease (Hagerstown, Md.)·2003
Same journal

A comparison of humanistic qualities among medical students, residents, and faculty physicians in internal medicine.

Heart disease (Hagerstown, Md.)·2003
Same journal

Effect of carotid angioplasty-stenting on short-term mortality and stroke.

Heart disease (Hagerstown, Md.)·2003
Same journal

Evidence for the extrapulmonary localization of inhaled nitric oxide.

Heart disease (Hagerstown, Md.)·2003
Same journal

Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart.

Heart disease (Hagerstown, Md.)·2003
See all related articles

Primary pulmonary hypertension (PPH) is a rare disease causing high blood pressure in lung arteries. Current treatments focus on lowering pressure and improving blood flow, with surgery as a last resort for severe cases.

Area of Science:

  • Cardiology
  • Pulmonology
  • Vascular Medicine

Background:

  • Primary pulmonary hypertension (PPH) is defined by elevated pulmonary artery pressure (PAP) without a known cause.
  • Dyspnea is the most frequent presenting symptom, alongside fatigue, chest pain, syncope, edema, and palpitations.
  • Median survival in the NIH-PPH registry was 2.8 years, highlighting the condition's severity.

Purpose of the Study:

  • To outline the diagnostic criteria and current management strategies for Primary Pulmonary Hypertension (PPH).
  • To review established and investigational treatments for PPH.
  • To discuss surgical considerations for refractory PPH cases.

Main Methods:

  • Diagnosis is confirmed by right heart catheterization, revealing mean PAP >25 mmHg at rest and >30 mmHg during exercise with normal pulmonary capillary wedge pressure.

Related Experiment Videos

  • Treatment strategies involve lowering PAP, enhancing cardiac output, and preventing thrombosis.
  • Medical management includes vasodilators (prostacyclin, calcium-channel blockers, nitric oxide, adenosine), anticoagulation, and supportive therapies (oxygen, digoxin, diuretics).

    • Main Results:

    • Vasodilators have shown some efficacy in PPH treatment.
    • Anticoagulation is recommended for preventing various thrombotic events.
    • Investigational drugs like L-arginine, plasma endothelin-I, and bosentan are under study.

    Conclusions:

    • PPH requires a multi-faceted treatment approach targeting hemodynamics and thrombosis.
    • Symptomatic relief and prevention of complications are key components of management.
    • Surgical intervention is reserved for severe PPH cases unresponsive to medical therapy.